The Cigna Group (NYSE:CI) is one of the 11 Dirt Cheap Stocks to Buy According to Analysts. On October 15, Wolfe Research lowered its price target on The Cigna Group (NYSE:CI) from $345 to $325 and kept an Outperform rating. Wolfe Research pointed out that even after moderating its numbers slightly, it still sees The Cigna Group’s (NYSE:CI) stock as cheap at about 9 times its revised 2026 EPS forecast. Wolfe Research Lowers Cigna (CI) Price Target but Keeps Outperform Rating The research firm believes Th ...

Core Viewpoint - Cigna Group is positioned as a strong player in the health services sector, with a potential for stock price appreciation and solid financial fundamentals [1][3][5] Company Overview - Cigna Group (NYSE:CI) offers a diverse range of insurance products and services across health services, international markets, and group disability and life segments [1] - The company competes with major health insurance players like UnitedHealth Group and Anthem [1] Stock Performance - Cigna's stock has seen a slight decline of approximately 0.68% over the past month, with a recent 10-day decline of about 0.81%, indicating potential market volatility [2] - This decline may present a buying opportunity for investors who believe in the company's long-term potential [2][5] Growth Potential - Cigna has a projected stock price increase of 29.26%, suggesting significant upside potential for investors [3][5] - The company's Piotroski Score of 8 indicates strong financial health and efficient operations, reflecting solid fundamentals [3][5] Analyst Insights - Analysts have set a target price of $380.75 for Cigna, indicating confidence in the stock's future performance based on its growth potential and financial metrics [4][5] - The recent local minimum in stock price could signal a rebound, presenting an opportune moment for investors to consider entering the market [4]

Core Insights - The Cigna Group (NYSE:CI) is highlighted as a strong investment opportunity within the defensive healthcare dividend stocks category [1] - Recent analyst upgrades from Goldman Sachs and Wells Fargo have increased interest in Cigna, with Goldman Sachs initiating coverage with a Buy rating and a price target of $370 [3][4] - Cigna has a consistent track record of dividend increases, having raised its dividend for five consecutive years, currently offering a quarterly dividend of $1.51 per share with a yield of 2.00% [5] Analyst Ratings - Goldman Sachs analyst Scott Fidel initiated coverage of Cigna with a Buy rating, citing a significant downturn in the managed care sector and anticipating a recovery phase starting in 2026, particularly in Medicare Advantage [3] - Wells Fargo raised its price target for Cigna from $340 to $354 while maintaining an Equal Weight rating, reflecting an updated outlook for the sector ahead of Q3 2025 earnings [4] Dividend Performance - Cigna has demonstrated strong appeal to income-focused investors by increasing its dividend for five consecutive years, currently providing a quarterly dividend of $1.51 per share [5]

Valued at a market cap of $80.6 billion, The Cigna Group (CI) is a global health services and insurance company based in Bloomfield, Connecticut. It provides medical, pharmacy, dental, behavioral health, and supplemental insurance solutions, along with pharmacy benefit management, care delivery, and health management services. The company is scheduled to announce its fiscal Q3 earnings for 2025 before the market opens on Thursday, Oct. 30. Ahead of this event, analysts expect this health insurance company ...

, /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), today released its Improving Youth Mental Health 2025 Impact Report, highlighting the transformative effect of its youth mental health initiatives across 10 states. With more than $3 million in grants distributed to 23 nonprofit organizations in its first year of the youth mental health grant program, the Foundation's commitment to improving mental health access and outcomes has reached over 34,000 youth, fami ...

Core Insights - Significant investors have adopted a bullish stance on Cigna Group, with 51% of trades being bullish and 32% bearish, indicating a positive outlook on the stock [1] - The expected price range for Cigna Group over the past three months is between $180.0 and $340.0, reflecting investor confidence [2] Options Trading Activity - A total of 31 trades were detected for Cigna Group, with 4 puts totaling $166,220 and 27 calls amounting to $1,515,514, showcasing a strong preference for call options [1] - The volume and open interest trends for Cigna Group's options indicate significant liquidity and interest, particularly within the strike price range of $180.0 to $340.0 [3][4] Company Overview - Cigna primarily offers pharmacy benefit management and health insurance services, significantly expanded through its 2018 merger with Express Scripts [9] - The company serves a large customer base, with 17 million US and 2 million international medical members covered as of December 2024 [10] Analyst Insights - Analysts have set an average price target of $383.0 for Cigna Group, reflecting a positive outlook on the stock's future performance [12] - Barclays maintains an Overweight rating for Cigna Group, reinforcing the bullish sentiment among analysts [13] Current Market Position - Cigna Group's stock price is currently at $314.3, up 5.83%, with a trading volume of 1,500,020, indicating strong market interest [15]

Financial Results Announcement - The Cigna Group will release its third quarter 2025 financial results on October 30, 2025, by 6:30 a.m. ET [1] - A conference call to discuss these results will take place at 8:30 a.m. ET on the same day [1][2] - Participants are encouraged to join the call by 8:15 a.m. ET, and a replay will be available from 12:30 p.m. ET on October 30 until 10:59 p.m. ET on November 13, 2025 [2] Company Overview - The Cigna Group is a global health company focused on improving health outcomes and community vitality [4] - The company operates under various brands, including Cigna Healthcare and Evernorth Health Services, and has a presence in over 30 markets with approximately 180 million customer relationships worldwide [4]

Group 1 - The Cigna Group (NYSE:CI) is highlighted by UBS as a top choice in the Healthcare Facilities & Managed Care sector, maintaining a Buy rating with a price target of $390 [1] - Cigna is recognized as the largest Managed Care Organization with low susceptibility to government business volatility [1] - The company is on a long-term earnings growth trajectory, supported by share buybacks, margin recovery in its stop loss business, and opportunities in specialty pharmacy [2] Group 2 - Despite industry concerns regarding Pharmacy Benefit Management reform, UBS believes that potential legislation will not significantly impact Cigna's earnings and may even serve as a clearing event for its shares [2] - Cigna specializes in providing insurance and associated services in the U.S., including pharmaceutical benefits, home delivery pharmacy, and specialty pharmacy distribution [3]

Core Insights - Cigna Group has approved coverage for Cleerly's AI-powered cardiovascular imaging technology, enhancing digital healthcare access for over 61 million Americans [1][3][10] - The integration of AI in healthcare is expected to improve early detection of heart disease, which is the leading cause of death in the U.S., and help manage healthcare costs [2][3] - Cigna's decision aligns with a broader trend towards value-based care and digital advancements, aiming to improve patient outcomes and reduce long-term healthcare expenses [4] Company Performance - Cigna reported a 13% year-over-year growth in total revenues in the first half of 2025 [5][10] - Competitors such as UnitedHealth Group, Elevance Health, and Humana are also focusing on value-based care, with UnitedHealth's Optum division achieving a 5.8% revenue growth and Humana reporting a 9.9% increase in adjusted revenues in the same period [6][7][9] Industry Trends - The adoption of AI technologies in healthcare is increasing, particularly in preventive care and population health management, which can lead to reduced hospitalization and emergency care costs [3] - The move towards integrated, patient-focused care is evident as companies expand their services beyond traditional insurance to include primary care and digital health solutions [8]

Market Overview - U.S. stock futures declined on Tuesday following gains on Monday, with major indices showing lower futures as a government shutdown looms [1][2] - The Dow Jones, S&P 500, Nasdaq 100, and Russell 2000 futures fell by 0.20%, 0.16%, 0.14%, and 0.19% respectively [3] Sector Performance - On Monday, information technology, financial, and consumer discretionary sectors led gains, while energy and communication services sectors closed lower [4] - Nvidia Corp. shares rose approximately 2%, with other AI-related stocks like AMD and Micron also gaining [5] Economic Indicators - U.S. pending home sales increased by 4% in August, marking the largest gain in five months, contrasting with a 0.4% decline in the previous month [6] - The 10-year Treasury bond yielded 4.13%, while the two-year bond was at 3.60%, indicating market expectations for potential interest rate cuts by the Federal Reserve [2] Analyst Insights - Economist Jeremy Siegel noted that inflation data aligns with market expectations, suggesting a stable economic environment conducive to further interest rate cuts [10][11] - Siegel projects full-year GDP growth around 2.4%-2.5%, indicating a healthy economy without overheating [12] - Goldman Sachs' strategist identified potential risks including a growth shock, rate shock, and a significant dollar devaluation that could impact market stability [15] Company-Specific Developments - Lamb Weston Holdings Inc. is expected to report earnings of 55 cents per share on revenue of $1.62 billion [18] - Paychex Inc. is projected to report earnings of $1.21 per share on revenue of $1.54 billion [18] - Progress Software Corp. raised its full-year 2025 revenue guidance to $975 million to $981 million, exceeding previous estimates [20]